Therapeutic Potentials of Inhibition of Jumonji C Domain - containing Demethylases in Acute Myeloid Leukemia

Creative Commons License

Koca D., Hastar N., Engur S., Kiraz Y., Ulu G. T., Cekdemir D., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.1, pp.5-12, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.4274/tjh.galenos.2019.2019.0083
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.5-12
  • Keywords: Acute myeloid leukemia, Methylstat, Jumonji C domain, Histone methylation, HISTONE DEMETHYLASES, BONE-MARROW, CANCER, METABOLISM
  • Anadolu University Affiliated: Yes


Objective: Acute myeloid leukemia (AML) is a complex disease affected by both genetic and epigenetic factors. Histone methylation and demethylation are types of epigenetic modification in chromatin remodeling and gene expression. Abnormal expression of histone demethylases is indicated in many types of cancer including AML Although many commercial drugs are available to treat AML, an absolute cure has not been discovered yet. However, inhibition of demethylases could be a potential cure for AML Methylstat is a chemical agent that inhibits the Jumonji C domain-containing demethylases.